Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
P/E ratio for AlloVir, Inc. (ALVR)
P/E ratio as of 2023: -0.37
According to AlloVir, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.37. At the end of 2022 the company had a P/E ratio of -2.33.
P/E ratio history for AlloVir, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.37 |
| 2022 | -2.33 |
| 2021 | -4.72 |
| 2020 | -15.12 |
| 2019 | -75.92 |
| 2018 | -387.62 |